Salvianolic acid B improves airway hyperresponsiveness by inhibiting MUC5AC overproduction associated with Erk1/2/P38 signaling
| Autor: | Yong-liang Jia, Jian Shen, Xin-wei Dong, Ya-chao Jin, Jianping Zhu, Yan Guan, Qiang-min Xie |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
MAP Kinase Signaling System p38 mitogen-activated protein kinases Inflammation Bronchi Pharmacology Mucin 5AC p38 Mitogen-Activated Protein Kinases Cell Line 03 medical and health sciences Mice Respiratory Hypersensitivity Medicine Animals Humans Anti-Asthmatic Agents Lung Sensitization Benzofurans Glycosaminoglycans Mitogen-Activated Protein Kinase 1 Mice Inbred BALB C Interleukin-13 Mitogen-Activated Protein Kinase 3 biology business.industry Mucin Interleukin respiratory system Eosinophil Asthma Trachea Ovalbumin 030104 developmental biology medicine.anatomical_structure Gene Expression Regulation Interleukin 13 biology.protein Female medicine.symptom business |
| Zdroj: | European journal of pharmacology. 824 |
| ISSN: | 1879-0712 |
| Popis: | Salvianolic acid B (SalB) is one of the main water-soluble composites from Chinese medicine Dansen (Radix miltiorrhiza). It is used for clinical treatment of various diseases including cardiovascular, lung, Liver, renal and cancers. However, the effects of SalB to allergy induced airway mucin hypersecretion, inflammation and hyperresponsiveness (AHR) remains not clear. Overproduction of airway MUC5AC is a central effector of inflammation that is strongly associated with AHR in asthmatic attack. In this study, we investigated the anti-asthmatic activity and mechanism of SalB in a murine model and human epithelial cells by monitoring changes in mucin expression and secretion, airway inflammation, AHR, and signaling pathways. SalB was administered by intragastric administration (i.g) daily for a week, starting at 21 days after sensitization of ovalbumin (OVA). All examinations were performed 24h after the last antigen challenge. We found that treatments with SalB significantly inhibited increase in the tracheobronchial secretion, glycosaminoglycan levels, interleukin (IL)-13, IL-4, and IL-5 cytokines mRNA and protein expression, and decrease in mucociliary clearance in lung tissues. Histological results demonstrated that SalB attenuated OVA-induced eosinophil infiltration, airway goblet cell hyperplasia, and MUC5AC and MUC5B mRNA and protein expression in lung tissues. SalB exhibited protective effects against AHR in OVA-challenged animals. In vitro, SalB significantly inhibited IL-13-induced MUC5AC and MUC5B mRNA and protein expression in human epithelial cells. These effects were blocked by SalB by downregulating the Erk1/2 and P38 signaling pathways. Taken together, these data indicate that treatment with SalB may improve AHR by inhibiting MUC5AC overproduction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect